Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.02.06
- Author:
Ziyi XU
1
;
Puyuan XING
1
;
Di MA
1
;
Yixiang ZHU
2
;
Jianming YING
1
;
Junling LI
1
Author Information
1. National Cancer Center/National Clinical Research Center for Cancer/Caner Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Affiliated Hospital of Guizhou Medical University, Guizhou Province Tumor Hospital, Guiyang 550004, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Radiotherapy;
Resectable IIIa/N2 non-small cell lung cancer;
Surgery
- MeSH:
Clinical Trials as Topic;
Combined Modality Therapy;
Humans;
Lung Neoplasms;
drug therapy;
radiotherapy;
surgery;
therapy;
Meta-Analysis as Topic;
Neoplasm Staging;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2019;22(2):111-117
- CountryChina
- Language:Chinese
-
Abstract:
Standard treatment for resectable IIIa/N2 non-small-cell lung cancer (NSCLC) is still under debate. Optional treatments include chemotherapy, radiotherapy and surgery, other options include target therapy and immunotherapy. Multidisciplinary treatment has therefore been emphasized by various clinical trials, including bimodality strategy which has been defined as chemotherapy plus surgery or chemotherapy plus radiotherapy, and trimodality treatment which refers to chemotherapy plus surgery and radiotherapy. However, there is still no consensus on the optimal strategy on treating resectable IIIa/N2 NSCLC. Therefore, we reviewed a series of phase II and III clinical trials as well as some meta-analyses and case reports to compare the efficacy of different strategies on survival of cN2 NSCLC, and concluded that for resectable IIIa/N2 NSCLC surgery is recommended, and that strategy of chemotherapy plus surgery may not achieve better survival than that of chemotherapy plus radiotherapy. Size of tumor as well as lymph nodes should be taken into account when choosing optimal therapy, so that promising individualized strategy could be given to patients with resectable stage IIIa/N2 NSCLC.
.
